Endotracheal calcineurin inhibition ameliorates injury in an experimental model of lung ischemia-reperfusion

Steven M. Woolley, Alexander S. Farivar, Babu V. Naidu, Matthew Rosengart, Robert Thomas, Charles Fraga, Michael S. Mulligan, Robert J. Keenan, Thomas M. Egan, Stephen D. Cassivi, Robert J. Korst

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objectives: We previously demonstrated that calcineurin inhibitors given intravenously ameliorate experimental lung ischemia-reperfusion injury. This study evaluates whether these effects can be achieved when these agents are delivered endotracheally. Methods: Left lungs of Long Evans rats were rendered ischemic for 90 minutes and reperfused for up to 4 hours. Treated animals received tacrolimus endotracheally at doses of 0.2, 0.1, or 0.025 mg/kg 60 minutes before ischemia. Injury was quantitated in terms of vascular permeability. Additional animals treated at a dose of 0.1 mg/kg were assessed for lung tissue myeloperoxidase content and bronchoalveolar lavage leukocyte content. Bronchoalveolar lavage fluid was assessed for cytokine and chemokine content by enzyme-linked immunosorbent assay. Tissue samples were processed for nuclear factor-κB activation, and blood levels of tacrolimus were measured in treated animals. Results: Left lung vascular permeability was reduced in treated animals in a dose-dependent fashion compared with controls. The protective effects correlated with a 47% (0.50% ± 0.06% vs 0.27% ± 0.08%, respectively) reduction in tissue myeloperoxidase, content (P < .004) and marked reductions in bronchoalveolar lavage leukocyte accumulation. This protection was also associated with decreased nuclear factor-κB activation and diminished expression of proinflammatory mediators. Blood tacrolimus levels in treated animals at 4 hours of reperfusion were undetectable. Conclusions: Tacrolimus administered endotracheally is protective against lung ischemia-reperfusion injury in our model. This protection is associated with a decrease in nuclear factor-κB activation, This route of tacrolimus administration broadens its potential clinical use and decreases concerns about systemic and renal toxicity. It may be a useful therapy in lung donors to protect against lung ischemia-reperfusion injury.

Original languageEnglish (US)
Pages (from-to)376-384
Number of pages9
JournalJournal of Thoracic and Cardiovascular Surgery
Volume127
Issue number2
DOIs
StatePublished - Feb 2004
Externally publishedYes

Fingerprint

Calcineurin
Reperfusion
Theoretical Models
Ischemia
Tacrolimus
Lung
Wounds and Injuries
Reperfusion Injury
Capillary Permeability
Bronchoalveolar Lavage
Peroxidase
Leukocytes
Long Evans Rats
Bronchoalveolar Lavage Fluid
Chemokines
Enzyme-Linked Immunosorbent Assay
Cytokines
Kidney

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Endotracheal calcineurin inhibition ameliorates injury in an experimental model of lung ischemia-reperfusion. / Woolley, Steven M.; Farivar, Alexander S.; Naidu, Babu V.; Rosengart, Matthew; Thomas, Robert; Fraga, Charles; Mulligan, Michael S.; Keenan, Robert J.; Egan, Thomas M.; Cassivi, Stephen D.; Korst, Robert J.

In: Journal of Thoracic and Cardiovascular Surgery, Vol. 127, No. 2, 02.2004, p. 376-384.

Research output: Contribution to journalArticle

Woolley, SM, Farivar, AS, Naidu, BV, Rosengart, M, Thomas, R, Fraga, C, Mulligan, MS, Keenan, RJ, Egan, TM, Cassivi, SD & Korst, RJ 2004, 'Endotracheal calcineurin inhibition ameliorates injury in an experimental model of lung ischemia-reperfusion', Journal of Thoracic and Cardiovascular Surgery, vol. 127, no. 2, pp. 376-384. https://doi.org/10.1016/j.jtcvs.2003.09.034
Woolley, Steven M. ; Farivar, Alexander S. ; Naidu, Babu V. ; Rosengart, Matthew ; Thomas, Robert ; Fraga, Charles ; Mulligan, Michael S. ; Keenan, Robert J. ; Egan, Thomas M. ; Cassivi, Stephen D. ; Korst, Robert J. / Endotracheal calcineurin inhibition ameliorates injury in an experimental model of lung ischemia-reperfusion. In: Journal of Thoracic and Cardiovascular Surgery. 2004 ; Vol. 127, No. 2. pp. 376-384.
@article{f0230af149134cb08ac72faafb9237d8,
title = "Endotracheal calcineurin inhibition ameliorates injury in an experimental model of lung ischemia-reperfusion",
abstract = "Objectives: We previously demonstrated that calcineurin inhibitors given intravenously ameliorate experimental lung ischemia-reperfusion injury. This study evaluates whether these effects can be achieved when these agents are delivered endotracheally. Methods: Left lungs of Long Evans rats were rendered ischemic for 90 minutes and reperfused for up to 4 hours. Treated animals received tacrolimus endotracheally at doses of 0.2, 0.1, or 0.025 mg/kg 60 minutes before ischemia. Injury was quantitated in terms of vascular permeability. Additional animals treated at a dose of 0.1 mg/kg were assessed for lung tissue myeloperoxidase content and bronchoalveolar lavage leukocyte content. Bronchoalveolar lavage fluid was assessed for cytokine and chemokine content by enzyme-linked immunosorbent assay. Tissue samples were processed for nuclear factor-κB activation, and blood levels of tacrolimus were measured in treated animals. Results: Left lung vascular permeability was reduced in treated animals in a dose-dependent fashion compared with controls. The protective effects correlated with a 47{\%} (0.50{\%} ± 0.06{\%} vs 0.27{\%} ± 0.08{\%}, respectively) reduction in tissue myeloperoxidase, content (P < .004) and marked reductions in bronchoalveolar lavage leukocyte accumulation. This protection was also associated with decreased nuclear factor-κB activation and diminished expression of proinflammatory mediators. Blood tacrolimus levels in treated animals at 4 hours of reperfusion were undetectable. Conclusions: Tacrolimus administered endotracheally is protective against lung ischemia-reperfusion injury in our model. This protection is associated with a decrease in nuclear factor-κB activation, This route of tacrolimus administration broadens its potential clinical use and decreases concerns about systemic and renal toxicity. It may be a useful therapy in lung donors to protect against lung ischemia-reperfusion injury.",
author = "Woolley, {Steven M.} and Farivar, {Alexander S.} and Naidu, {Babu V.} and Matthew Rosengart and Robert Thomas and Charles Fraga and Mulligan, {Michael S.} and Keenan, {Robert J.} and Egan, {Thomas M.} and Cassivi, {Stephen D.} and Korst, {Robert J.}",
year = "2004",
month = "2",
doi = "10.1016/j.jtcvs.2003.09.034",
language = "English (US)",
volume = "127",
pages = "376--384",
journal = "Journal of Thoracic and Cardiovascular Surgery",
issn = "0022-5223",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Endotracheal calcineurin inhibition ameliorates injury in an experimental model of lung ischemia-reperfusion

AU - Woolley, Steven M.

AU - Farivar, Alexander S.

AU - Naidu, Babu V.

AU - Rosengart, Matthew

AU - Thomas, Robert

AU - Fraga, Charles

AU - Mulligan, Michael S.

AU - Keenan, Robert J.

AU - Egan, Thomas M.

AU - Cassivi, Stephen D.

AU - Korst, Robert J.

PY - 2004/2

Y1 - 2004/2

N2 - Objectives: We previously demonstrated that calcineurin inhibitors given intravenously ameliorate experimental lung ischemia-reperfusion injury. This study evaluates whether these effects can be achieved when these agents are delivered endotracheally. Methods: Left lungs of Long Evans rats were rendered ischemic for 90 minutes and reperfused for up to 4 hours. Treated animals received tacrolimus endotracheally at doses of 0.2, 0.1, or 0.025 mg/kg 60 minutes before ischemia. Injury was quantitated in terms of vascular permeability. Additional animals treated at a dose of 0.1 mg/kg were assessed for lung tissue myeloperoxidase content and bronchoalveolar lavage leukocyte content. Bronchoalveolar lavage fluid was assessed for cytokine and chemokine content by enzyme-linked immunosorbent assay. Tissue samples were processed for nuclear factor-κB activation, and blood levels of tacrolimus were measured in treated animals. Results: Left lung vascular permeability was reduced in treated animals in a dose-dependent fashion compared with controls. The protective effects correlated with a 47% (0.50% ± 0.06% vs 0.27% ± 0.08%, respectively) reduction in tissue myeloperoxidase, content (P < .004) and marked reductions in bronchoalveolar lavage leukocyte accumulation. This protection was also associated with decreased nuclear factor-κB activation and diminished expression of proinflammatory mediators. Blood tacrolimus levels in treated animals at 4 hours of reperfusion were undetectable. Conclusions: Tacrolimus administered endotracheally is protective against lung ischemia-reperfusion injury in our model. This protection is associated with a decrease in nuclear factor-κB activation, This route of tacrolimus administration broadens its potential clinical use and decreases concerns about systemic and renal toxicity. It may be a useful therapy in lung donors to protect against lung ischemia-reperfusion injury.

AB - Objectives: We previously demonstrated that calcineurin inhibitors given intravenously ameliorate experimental lung ischemia-reperfusion injury. This study evaluates whether these effects can be achieved when these agents are delivered endotracheally. Methods: Left lungs of Long Evans rats were rendered ischemic for 90 minutes and reperfused for up to 4 hours. Treated animals received tacrolimus endotracheally at doses of 0.2, 0.1, or 0.025 mg/kg 60 minutes before ischemia. Injury was quantitated in terms of vascular permeability. Additional animals treated at a dose of 0.1 mg/kg were assessed for lung tissue myeloperoxidase content and bronchoalveolar lavage leukocyte content. Bronchoalveolar lavage fluid was assessed for cytokine and chemokine content by enzyme-linked immunosorbent assay. Tissue samples were processed for nuclear factor-κB activation, and blood levels of tacrolimus were measured in treated animals. Results: Left lung vascular permeability was reduced in treated animals in a dose-dependent fashion compared with controls. The protective effects correlated with a 47% (0.50% ± 0.06% vs 0.27% ± 0.08%, respectively) reduction in tissue myeloperoxidase, content (P < .004) and marked reductions in bronchoalveolar lavage leukocyte accumulation. This protection was also associated with decreased nuclear factor-κB activation and diminished expression of proinflammatory mediators. Blood tacrolimus levels in treated animals at 4 hours of reperfusion were undetectable. Conclusions: Tacrolimus administered endotracheally is protective against lung ischemia-reperfusion injury in our model. This protection is associated with a decrease in nuclear factor-κB activation, This route of tacrolimus administration broadens its potential clinical use and decreases concerns about systemic and renal toxicity. It may be a useful therapy in lung donors to protect against lung ischemia-reperfusion injury.

UR - http://www.scopus.com/inward/record.url?scp=10744228106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744228106&partnerID=8YFLogxK

U2 - 10.1016/j.jtcvs.2003.09.034

DO - 10.1016/j.jtcvs.2003.09.034

M3 - Article

VL - 127

SP - 376

EP - 384

JO - Journal of Thoracic and Cardiovascular Surgery

JF - Journal of Thoracic and Cardiovascular Surgery

SN - 0022-5223

IS - 2

ER -